

**Original citation:**

Parashar, D., Bowden, Jack, Starr, Colin, Wernisch, Lorenz and Mander, Adrian. (2013) Adaptive enrichment in biomarker-stratified clinical trial design. *Trials*, 14 (Suppl 1). O11.

**Permanent WRAP url:**

<http://wrap.warwick.ac.uk/73741>

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution 2.0 Generic (CC BY 2.0) license and may be reused according to the conditions of the license. For more details see: <http://creativecommons.org/licenses/by/2.0/>

**A note on versions:**

The version presented in WRAP is the published version, or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: [publications@warwick.ac.uk](mailto:publications@warwick.ac.uk)

warwick**publications**wrap

highlight your research

<http://wrap.warwick.ac.uk>

ORAL PRESENTATION

Open Access

# Adaptive enrichment in biomarker-stratified clinical trial design

Deepak Parashar<sup>1,2\*</sup>, Jack Bowden<sup>2</sup>, Colin Starr<sup>2</sup>, Lorenz Wernisch<sup>2</sup>, Adrian Mander<sup>2</sup>

From 2nd Clinical Trials Methodology Conference: Methodology Matters  
Edinburgh, UK. 18-19 November 2013

In Phase II oncology trials, targeted therapies are being constantly evaluated for their efficacy in specific populations of interest. Such trials require designs that allow for stratification based on the participants' biomarker signature. One of the disadvantages of a targeted design (defined as enrichment in biomarker-positive sub-population) is that if the drug has at least some activity in the biomarker-negative subjects, then their effect in the biomarker-negative population may never be known.

Jones and Holmgren (JH) have proposed a design to determine whether drug has activity only in target population or the general population. Their design is an enrichment adaptation based on two parallel Simon two-stage designs. Unfortunately, there are several pitfalls in the JH design: the issue of hypothesis testing is not properly addressed and the type I error, power calculations and expected sample size formulae are wrong too.

We study the JH design in detail, appropriately control the type I and type II error probabilities that yield novel optimal designs. We also discuss various alternative Family Wise Error Rates (FWER) and the Individual Hypothesis (IH) error rates in the weak sense as well as the strong sense.

For each option of the error controls, we search for designs over a 10 trillion search space and obtain optimal designs that minimise the expected sample size. For the particular example trial that JH consider, our optimal design requires 38% fewer subjects in comparison with the two parallel Simon two-stage design thereby offering substantial efficiency in terms of the expected sample size. In conclusion, our rectified design provides a robust framework for adaptive enrichment in biomarker-stratified Phase II trial design.

#### Authors' details

<sup>1</sup>Cambridge Cancer Trials Centre, Cambridge, UK. <sup>2</sup>MRC Biostatistics Unit, Cambridge, UK.

Published: 29 November 2013

doi:10.1186/1745-6215-14-S1-O11

Cite this article as: Parashar *et al.*: Adaptive enrichment in biomarker-stratified clinical trial design. *Trials* 2013 **14**(Suppl 1):O11.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Cambridge Cancer Trials Centre, Cambridge, UK  
Full list of author information is available at the end of the article